Analysis of the Results of intravesical perfusion Therapy Combined with Immediate or non-immediate hematoporphyrin intravesical perfusion photodynamic therapy after TURBT for Non-muscle-invasive Bladder Cancer

To understand whether there are differences in the prevention of bladder cancer recurrence between intravesical perfusion therapy combined with immediate or non-immediate photodynamic therapy(PDT) with hematoporphyrin for NMIBC. In addition to the routine intravesical perfusion therapy, intravesical PDT was added for NMIBC,. Immediate intravesical hematoporphyrin intravesical perfusion photodynamic therapy (imPDT) or non-imPDT, The primary end point was RFS within 24 months. A total of 86 patients were included in the analysis. 33 patients received im-PDT and 53 patients received non-imPDT, There were no differences in Basic characteristics between the two groups. The median follow-up was 51.4 months. The 24-month recurrence rates of cancer in the imPDT group and non-imPDT group were no statistically significant differences. There was no statistically significant difference in the recurrence rate of cancer within 24 months for NMIBC between imPDT group and non-imPDT group